{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Avalo Therapeutics, Inc."},"Symbol":{"label":"Symbol","value":"AVTX"},"Address":{"label":"Address","value":"540 GAITHER ROAD SUITE 400, ROCKVILLE, Maryland, 20850, United States"},"Phone":{"label":"Phone","value":"+1 410 522-8707"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Avalo Therapeutics Inc is a clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical needs in immunology, immuno-oncology, and rare genetic diseases. Its pipeline consists of product candidates advancing in development with ongoing clinical programs: AVTX-002, AVTX-007, and AVTX-006."},"CompanyUrl":{"label":"Company Url","value":"https://www.avalotx.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Garry Arthur Neil","title":"Chairman, President &amp; Chief Executive Officer"},{"name":"Lisa Hegg","title":"Vice President-Research &amp; Development Programs"},{"name":"Pericles Calias","title":"Chief Scientific Officer, Head-R&amp;D"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}